IN2014DN06220A - - Google Patents

Download PDF

Info

Publication number
IN2014DN06220A
IN2014DN06220A IN6220DEN2014A IN2014DN06220A IN 2014DN06220 A IN2014DN06220 A IN 2014DN06220A IN 6220DEN2014 A IN6220DEN2014 A IN 6220DEN2014A IN 2014DN06220 A IN2014DN06220 A IN 2014DN06220A
Authority
IN
India
Prior art keywords
exons
dystrophin gene
human dystrophin
oligomer
drug
Prior art date
Application number
Other languages
English (en)
Inventor
Naoki Watanabe
Haruna Seo
Shinichi Takeda
Tetsuya Nagata
Original Assignee
Nippon Shinyaku Co Ltd
Nat Ct Neurology & Psychiatry
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd, Nat Ct Neurology & Psychiatry filed Critical Nippon Shinyaku Co Ltd
Publication of IN2014DN06220A publication Critical patent/IN2014DN06220A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IN6220DEN2014 2011-12-28 2012-12-27 IN2014DN06220A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011288040 2011-12-28
JP2012043092 2012-02-29
PCT/JP2012/084295 WO2013100190A1 (fr) 2011-12-28 2012-12-27 Acide nucléique antisens

Publications (1)

Publication Number Publication Date
IN2014DN06220A true IN2014DN06220A (fr) 2015-10-23

Family

ID=48697653

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6220DEN2014 IN2014DN06220A (fr) 2011-12-28 2012-12-27

Country Status (12)

Country Link
US (5) US9512424B2 (fr)
EP (2) EP3594347A1 (fr)
JP (6) JP6141770B2 (fr)
KR (2) KR102071729B1 (fr)
CN (10) CN108611349A (fr)
AU (2) AU2012360702C1 (fr)
CA (2) CA2861247C (fr)
ES (1) ES2748868T3 (fr)
IN (1) IN2014DN06220A (fr)
RU (3) RU2619184C2 (fr)
TW (1) TWI606059B (fr)
WO (1) WO2013100190A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2933332A1 (fr) 2004-06-28 2015-10-21 The University Of Western Australia Oligonucléotides antisens permettant d'induire un saut d'exon et leurs procédés d'utilisation
EP1855694B1 (fr) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Composition antisens permettant de traiter une atrophie musculaire
ES2639852T3 (es) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
EP2119783A1 (fr) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Procédé pour l'omission efficace de l'exon (44) dans la dystrophie musculaire de Duchenne et moyens connexes
BR122020021379B1 (pt) 2008-10-24 2021-05-11 Sarepta Therapeutics, Inc. oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
TR201816523T4 (tr) 2009-11-12 2018-11-21 Univ Western Australia Patolojilerin tedavisine yönelik antisens moleküller ve yöntemler.
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
CA2861247C (fr) * 2011-12-28 2021-11-16 Nippon Shinyaku Co., Ltd. Acide nucleique antisens
NZ627896A (en) 2012-01-27 2016-11-25 Biomarin Technologies B V Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
CN110218727A (zh) 2013-03-14 2019-09-10 萨勒普塔医疗公司 用于治疗肌营养不良的外显子跳跃组合物
US20140329762A1 (en) 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
DK3118311T3 (en) * 2014-03-12 2019-03-11 Nippon Shinyaku Co Ltd Antisense nucleic acid
CA2948139A1 (fr) * 2014-05-19 2015-11-26 Knc Laboratories Co., Ltd. Medicament a base d'acide nucleique destine a induire un saut d'exon de variant du gene cd44 et a augmenter l'expression de l'arnm du cd44 de type normal
MX373052B (es) 2014-06-17 2020-05-11 Nippon Shinyaku Co Ltd Acidos nucleicos antisentido.
WO2016060135A1 (fr) * 2014-10-14 2016-04-21 味の素株式会社 Procédé de préparation d'oligonucléotides de type morpholino
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
HUE050061T2 (hu) * 2015-09-15 2020-12-28 Nippon Shinyaku Co Ltd Antiszensz nukleinsav
IL295755A (en) 2015-10-09 2022-10-01 Wave Life Sciences Ltd Oligonucleotide compositions and methods thereof
EP3858993A1 (fr) 2015-10-09 2021-08-04 Sarepta Therapeutics, Inc. Compositions et procédés pour le traitement de la dystrophie musculaire de duchenne et de troubles apparentés
MD3464306T2 (ro) * 2016-05-24 2024-08-31 Sarepta Therapeutics Inc Procedee de preparare a oligomerilor morfolino fosforodiamidați
BR112018074346B1 (pt) * 2016-05-24 2023-01-03 Sarepta Therapeutics, Inc. Composto oligomérico e processo para preparar um composto oligomérico
JP2019525742A (ja) * 2016-06-30 2019-09-12 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマー
WO2018107003A1 (fr) * 2016-12-08 2018-06-14 The Board Of Regents Of The University Of Texas System Modèles rapporteurs de la dmd contenant des mutations humanisées de myopathie de duchenne
PT3554552T (pt) 2016-12-19 2022-10-03 Sarepta Therapeutics Inc Conjugados de oligómero de skipping de exão para distrofia muscular
KR102810425B1 (ko) 2016-12-19 2025-05-21 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
KR20240006023A (ko) 2016-12-19 2024-01-12 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
EA201991450A1 (ru) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
WO2019067981A1 (fr) 2017-09-28 2019-04-04 Sarepta Therapeutics, Inc. Polythérapies pour traiter une dystrophie musculaire
US10758629B2 (en) 2018-05-29 2020-09-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
SG11202100928QA (en) 2018-08-02 2021-02-25 Dyne Therapeutics Inc Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
CA3108282A1 (fr) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Complexes de ciblage musculaire et leurs utilisations pour le traitement de dystrophinopathies
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
IL318474A (en) * 2018-12-13 2025-03-01 Sarepta Therapeutics Inc Axon-skipping oligomer complexes for muscular dystrophy
US20220144902A1 (en) * 2018-12-25 2022-05-12 National Center Of Neurology And Psychiatry Method for inducing muscular cells using cells in spot urine
WO2020219820A1 (fr) 2019-04-25 2020-10-29 Avidity Biosciences, Inc. Compositions d'acide nucléique et méthodes de saut multi-exon
IL293997A (en) 2019-12-19 2022-08-01 Nippon Shinyaku Co Ltd Antistrand nucleic acids that allow exon skipping
CN114901823A (zh) * 2019-12-26 2022-08-12 日本新药株式会社 诱导外显子50的跳读的反义核酸
IL295967A (en) * 2020-02-28 2022-10-01 Nippon Shinyaku Co Ltd Antisense nucleic acids for splicing on exon 51
IL307937A (en) 2021-04-30 2023-12-01 Sarepta Therapeutics Inc Treatment methods for muscular dystrophy
CN117321205A (zh) 2021-05-13 2023-12-29 国立大学法人千叶大学 反义寡聚物
WO2022270585A1 (fr) 2021-06-23 2022-12-29 日本新薬株式会社 Combinaison d'oligomères antisens
CA3225573A1 (fr) 2021-07-08 2023-01-12 Nippon Shinyaku Co., Ltd. Inhibiteur de precipitation
TW202308664A (zh) 2021-07-08 2023-03-01 日商日本新藥股份有限公司 腎毒性減輕劑
CN118475355A (zh) 2021-07-08 2024-08-09 日本新药株式会社 肾毒性减轻剂
JP2024525608A (ja) 2021-07-09 2024-07-12 ダイン セラピューティクス，インコーポレーテッド ジストロフィン異常症を処置するための筋標的化複合体および製剤
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
JP2024525611A (ja) * 2021-07-09 2024-07-12 ダイン セラピューティクス，インコーポレーテッド 筋標的化複合体およびジストロフィノパチーを処置するためのその使用
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
US20240390508A1 (en) 2021-08-21 2024-11-28 Takeda Pharmaceutical Company Limited Human transferrin receptor binding peptide-drug conjugate
EP4458833A4 (fr) 2021-12-27 2025-12-31 Nippon Shinyaku Co Ltd Procédé de production de composé d'acide oligonucléique
WO2023168427A1 (fr) 2022-03-03 2023-09-07 Yale University Compositions et procédés d'administration de polynucléotides thérapeutiques pour saut d'exon
JP2025079347A (ja) * 2022-03-11 2025-05-22 日本新薬株式会社 キャリアペプチドが連結された核酸
CN119013401A (zh) 2022-03-17 2024-11-22 萨勒普塔医疗公司 二氨基磷酸酯吗啉代寡聚物缀合物
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU655164B2 (en) 1989-12-20 1994-12-08 Antivirals Inc. Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages
JP2924179B2 (ja) 1993-02-19 1999-07-26 日本新薬株式会社 グリセロール誘導体，デバイス及び医薬組成物
SK282843B6 (sk) * 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
US6727355B2 (en) * 2000-08-25 2004-04-27 Jcr Pharmaceuticals Co., Ltd. Pharmaceutical composition for treatment of Duchenne muscular dystrophy
EP1191097A1 (fr) * 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction du "exon-skipping" dans des cellules eukaryotes
EP2392660A3 (fr) * 2002-11-25 2012-03-28 Masafumi Matsuo Médicaments à base d'acide nucléique ENA modifiant l'épissage dans un précurseur d'ARNm
AU2003225410A1 (en) 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
EP2933332A1 (fr) 2004-06-28 2015-10-21 The University Of Western Australia Oligonucléotides antisens permettant d'induire un saut d'exon et leurs procédés d'utilisation
WO2006038608A1 (fr) 2004-10-05 2006-04-13 Nippon Shinyaku Co., Ltd. Oligo arn à double brin et composition medicinale
WO2006112705A2 (fr) * 2005-04-22 2006-10-26 Academisch Ziekenhuis Leiden Modulation de la reconnaissance d'exon dans un pre-arnm par interference avec la liaison de proteines sr et interference avec une structure d'arn secondaire
EP1886688A4 (fr) 2005-05-30 2013-01-09 Nippon Shinyaku Co Ltd Procédé servant à produire une préparation complexe contenant des acides nucléiques
US8067571B2 (en) * 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
EP1857548A1 (fr) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Procédé et moyen permettant d'induire un saut d'exon
JP5347510B2 (ja) 2007-02-05 2013-11-20 日本新薬株式会社 ポリエチレングリコール誘導体
ES2639852T3 (es) 2007-10-26 2017-10-30 Academisch Ziekenhuis Leiden Medios y métodos para contrarrestar los trastornos musculares
RU2606627C2 (ru) 2007-11-15 2017-01-10 Серепта Терапьютикс,Инк. Способ синтеза морфолиновых олигомеров
EP2119783A1 (fr) * 2008-05-14 2009-11-18 Prosensa Technologies B.V. Procédé pour l'omission efficace de l'exon (44) dans la dystrophie musculaire de Duchenne et moyens connexes
US8084601B2 (en) 2008-09-11 2011-12-27 Royal Holloway And Bedford New College Royal Holloway, University Of London Oligomers
BR122020021379B1 (pt) 2008-10-24 2021-05-11 Sarepta Therapeutics, Inc. oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
AU2009310557B2 (en) 2008-10-27 2014-09-11 Academisch Ziekenhuis Leiden Methods and means for efficient skipping of exon 45 in Duchenne Muscular Dystrophy pre-mRNA
EP2421971B1 (fr) * 2009-04-24 2016-07-06 BioMarin Technologies B.V. Oligonucléotides comportant une inosine pour le traitement de dmd
US20120270930A1 (en) * 2009-10-29 2012-10-25 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Methods and compositions for dysferlin exon-skipping
TR201816523T4 (tr) * 2009-11-12 2018-11-21 Univ Western Australia Patolojilerin tedavisine yönelik antisens moleküller ve yöntemler.
KR20200133284A (ko) * 2010-05-28 2020-11-26 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
JP5593949B2 (ja) 2010-08-17 2014-09-24 横河電機株式会社 プログラマブルロジックコントローラ
CA2861247C (fr) * 2011-12-28 2021-11-16 Nippon Shinyaku Co., Ltd. Acide nucleique antisens

Also Published As

Publication number Publication date
CN110055243B (zh) 2024-03-26
CN107881175B (zh) 2022-05-13
CN108611349A (zh) 2018-10-02
JP2024038103A (ja) 2024-03-19
KR20140108676A (ko) 2014-09-12
CN108588073A (zh) 2018-09-28
US20210222169A1 (en) 2021-07-22
EP2799548B1 (fr) 2019-08-21
EP2799548A1 (fr) 2014-11-05
EP3594347A1 (fr) 2020-01-15
EP2799548A4 (fr) 2015-11-18
CN107881175A (zh) 2018-04-06
CN110079525A (zh) 2019-08-02
AU2012360702A1 (en) 2014-07-24
ES2748868T3 (es) 2020-03-18
US20170067052A1 (en) 2017-03-09
CN118207212A (zh) 2024-06-18
CN108486116A (zh) 2018-09-04
US9512424B2 (en) 2016-12-06
KR20200008663A (ko) 2020-01-28
TW201336859A (zh) 2013-09-16
CA2861247A1 (fr) 2013-07-04
US20250188459A1 (en) 2025-06-12
AU2018229530B2 (en) 2021-05-13
CA3132111A1 (fr) 2013-07-04
US9890381B2 (en) 2018-02-13
JP6734222B2 (ja) 2020-08-05
CN110055243A (zh) 2019-07-26
WO2013100190A1 (fr) 2013-07-04
CN104024414A (zh) 2014-09-03
AU2018229530A1 (en) 2018-10-04
US20140343266A1 (en) 2014-11-20
JP2025176110A (ja) 2025-12-03
US10781448B2 (en) 2020-09-22
JP2020114215A (ja) 2020-07-30
AU2012360702C1 (en) 2018-09-20
RU2681470C1 (ru) 2019-03-06
CA2861247C (fr) 2021-11-16
RU2014130600A (ru) 2016-02-20
RU2651468C1 (ru) 2018-04-19
JP6141770B2 (ja) 2017-06-07
US20180142245A1 (en) 2018-05-24
TWI606059B (zh) 2017-11-21
JP2017163994A (ja) 2017-09-21
JP2022058379A (ja) 2022-04-12
JPWO2013100190A1 (ja) 2015-05-11
KR102240139B1 (ko) 2021-04-13
CN110055244A (zh) 2019-07-26
AU2012360702B2 (en) 2018-06-28
JP7038365B2 (ja) 2022-03-18
KR102071729B1 (ko) 2020-01-31
CN117721110A (zh) 2024-03-19
RU2619184C2 (ru) 2017-05-12

Similar Documents

Publication Publication Date Title
IN2014DN06220A (fr)
PH12019502292A1 (en) Methods and compositions for treatment of a genetic condition
EP2828275A4 (fr) Synthèse de trisaccharide de type 3-o-fucosyllactose et de ses intermédiaires
MY193708A (en) Antisense nucleic acids
SI3378862T1 (sl) Dihidropirimidinoizokuinolini in farmacevtski sestavki le-teh za zdravljenje multiple skleroze
IL225769A0 (en) Piperidine-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
PH12015500525A1 (en) Formulations of enzalutamide
IT1401855B1 (it) Apparecchiatura per il trattamento di un prodotto.
IL225815A0 (en) Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
ZA201307956B (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
HUE036248T2 (hu) Aminoglükozidok és alkalmazásaik genetikai rendellenességek kezelésére
IN2014CN00795A (fr)
EP3052654A4 (fr) Identification de petites molécules de structure semblable, qui amplifient un saut d'exon thérapeutique
IL223289A0 (en) Treatment of type 2 diabetes
EP2665706A1 (fr) Nouveaux 4-amino-n-hydroxy-benzamides en tant qu'inhibiteurs de hdac pour le traitement du cancer
EP2971156A4 (fr) Gènes et signatures géniques pour le diagnostic et le traitement du mélanome
IL225406A0 (en) Therapeutic applications of smad7
EP2798450A4 (fr) Affichage d'éléments
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
MY165088A (en) Pharmaceutical compositions comprising alisporivir
ZA201306420B (en) Regulated gene expression systems and constructs thereof
ZA201408058B (en) Compositions and methods for the treatment of epilepsy
IL237781A0 (en) A novel phenylacetamide compound, and a drug containing it
IN2015DN02647A (fr)
IT1403250B1 (it) Macroapparato per la produzione e il trattamento di gas